Helpful Insights forPatients and Caregivers

Download PDF

When proper doses of psychedelics are taken, most describe their experiences as “out of body” with a new stream of consciousness. This may be key in the treatment of various psychiatric conditions.


  1. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. May 2019;197:83-102. doi:10.1016/j.pharmthera.2018.11.010
  2. Dominguez-Clave E, Soler J, Elices M, et al. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull. Sep 2016;126(Pt 1):89-101. doi:10.1016/j.brainresbull.2016.03.002
  3. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. Mar 2019;49(4):655-663. doi:10.1017/S0033291718001356
  4. Administration USDE. Fact Sheets. Accessed 9/15, 2023.
  5. Uthaug MV, Davis AK, Haas TF, et al. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol. Mar 2022;36(3):309-320. doi:10.1177/02698811211013583
  6. Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules. May 15 2021;26(10)doi:10.3390/molecules26102948
  7. Richert L, Dyck E. Psychedelic crossings: American mental health and LSD in the 1970s. Med Humanit. Sep 2020;46(3):184-191. doi:10.1136/medhum-2018-011593
  8. Varker T, Watson L, Gibson K, Forbes D, O'Donnell ML. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. J Psychoactive Drugs. Jan-Mar 2021;53(1):85-95. doi:10.1080/02791072.2020.1817639
  9. Passie T, Benzenhofer U. MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). Drug Test Anal. Jan 2018;10(1):72-80. doi:10.1002/dta.2292
  10. Figurasin R, Maguire NJ. 3,4-Methylenedioxy-Methamphetamine Toxicity. StatPearls. 2023.
  11. Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry (2023).
  12. Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Curr Neuropharmacol. 2019;17(2):108-128. doi:10.2174/1570159X16666180125095902
  13. Sanches RF, de Lima Osorio F, Dos Santos RG, et al. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. J Clin Psychopharmacol. Feb 2016;36(1):77-81. doi:10.1097/JCP.0000000000000436
  14. Patterson E. Common Street Names for Drugs. Accessed 9/15, 2023.
  15. Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. Nov 2022;25(11):1407-1419. doi:10.1038/s41593-022-01177-4
  16. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Curr Mol Pharmacol. 2019;12(3):184-194. doi:10.2174/1874467211666181010154139
  17. Husain MI, Blumberger DM, Castle DJ, et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open. Jul 25 2023;9(4):e134. doi:10.1192/bjo.2023.535
  18. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. Jul 2016;3(7):619-27. doi:10.1016/S2215-0366(16)30065-7
  19. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). Feb 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x
  20. Ching THW, Grazioplene R, Bohner C, et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023;14:1178529. doi:10.3389/fpsyt.2023.1178529
  21. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. Nov 2014;28(11):983-92. doi:10.1177/0269881114548296
  22. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. Jan 2017;43(1):55-60. doi:10.3109/00952990.2016.1170135
  23. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. Mar 2015;29(3):289-99. doi:10.1177/0269881114565144
  24. Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. May 1 2020;177(5):391-410. doi:10.1176/appi.ajp.2019.19010035
  25. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. Jul 2012;26(7):994-1002. doi:10.1177/0269881112439253
  26. Agin-Liebes G, Nielson EM, Zingman M, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis. Psychol Addict Behav. Jun 5 2023;doi:10.1037/adb0000935
  27. Traynor JM, Roberts DE, Ross S, Zeifman R, Choi-Kain L. MDMA-Assisted Psychotherapy for Borderline Personality Disorder. Focus (Am Psychiatr Publ). Oct 2022;20(4):358-367. doi:10.1176/appi.focus.20220056
  28. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. Jun 2021;27(6):1025-1033. doi:10.1038/s41591-021-01336-3
  29. Lear MK, Smith SM, Pilecki B, Stauffer CS, Luoma JB. Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol. Front Psychiatry. 2023;14:1083354. doi:10.3389/fpsyt.2023.1083354
  30. Mitchell JM, Ot'alora GM, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. Sep 14 2023;doi:10.1038/s41591-023-02565-4
  31. Rudnick G, Wall SC. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A. Mar 1 1992;89(5):1817-21. doi:10.1073/pnas.89.5.1817
  32. van Dijken GD, Blom RE, Hene RJ, Boer WH, Consortium N. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dial Transplant. Sep 2013;28(9):2277-83. doi:10.1093/ndt/gft023
  33. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. Aug 2008;22(6):603-20. doi:10.1177/0269881108093587
  34. Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol. Mar 2022;36(3):258-272. doi:10.1177/02698811211069100
  35. Johansen PO, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. Mar 2015;29(3):270-9. doi:10.1177/0269881114568039